Serious arterial thromboembolic events (sATE) in patients (PTS) with metastatic colorectal cancer (MCRC) treated with bevacizumab (BV): Results from the BRiTE registry

被引：0
|
作者：
Sugrue, M.
Yi, J.
Purdie, D.
Dong, W.
Grothey, A.
Kozoff, M.
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Mayo Clin, Rochester, MN USA
[3] Ingalls Hosp, Harvey, IL USA
[4] Univ Chicago, Harvey, IL USA
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：VII30 / VII30
页数：1
相关论文
共 50 条
  • [31] VEGF GENE POLYMORPHISMS IN THE PREDICTION OF BENEFIT FROM FIRST-LINE FOLFIRI PLUS BEVACIZUMAB (BV) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS)
    Loupakis, F.
    Ruzzo, A.
    Salvatore, L.
    Canestrari, E.
    Cremolini, C.
    Masi, G.
    Schirripa, M.
    Spoto, C.
    Galluccio, N.
    Vincenzi, B.
    Santini, D.
    Bencardino, K.
    Ricci, V
    Catalano, V
    Manzoni, M.
    Danova, M.
    Tonini, G.
    Magnani, M.
    Falcone, A.
    Graziano, F.
    ANNALS OF ONCOLOGY, 2009, 20
  • [32] Safety and effectiveness of bevacizumas (BV) plus chemotherapy (CT) in elderly patients with MCRC: Results from the brite registry
    Sugrue, M.
    Kozloff, M.
    Hainsworth, J.
    Badarinath, S.
    Cohn, A.
    Flynn, P.
    Dong, W.
    Suzuki, S.
    Purdie, D.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2007, 18 : VII87 - VII87
  • [33] BASELINE LEVELS OF CIRCULATING ANGIOGENIC FACTORS IN METASTATIC COLORECTAL CANCER PTS (MCRC) TREATED WITH BEVACIZUMAB (BEV)
    Martinetti, A.
    Bajetta, E.
    Dibartolomeo, M.
    Dotti, K. F.
    Bianchi, F.
    Sottotetti, E.
    Gevorgyan, A.
    Celio, L.
    Fossile, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 66 - 66
  • [34] Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
    Tebbutt, N. C.
    Murphy, F.
    Zannino, D.
    Wilson, K.
    Cummins, M. M.
    Abdi, E.
    Strickland, A. H.
    Lowenthal, R. M.
    Marx, G.
    Karapetis, C.
    Shannon, J.
    Goldstein, D.
    Nayagam, S. S.
    Blum, R.
    Chantrill, L.
    Simes, R. J.
    Price, T. J.
    ANNALS OF ONCOLOGY, 2011, 22 (08) : 1834 - 1838
  • [35] Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).
    Cremolini, Chiara
    Loupakis, Fotios
    Yang, Dongyun
    Salvatore, Lisa
    Zhang, Wu
    Wakatsuki, Takeru
    Schirripa, Marta
    Lonardi, Sara
    Antoniotti, Carlotta
    Aprile, Giuseppe
    Masi, Gianluca
    Graziano, Francesco
    Ruzzo, Annamaria
    Lucchesi, Sara
    Ronzoni, Monica
    Maus, Martin Karl Herbert
    Bocci, Guido
    Tonini, Giuseppe
    Falcone, Alfredo
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Baron, A. D.
    O'Bryant, C. L.
    Choi, Y.
    Ashkenazi, A.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [37] Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen. results from the brite observational cohort study
    Kozloff, M.
    Sugrue, M.
    Chiruvolu, P.
    Feng, S.
    Purdie, D.
    Grothey, A.
    Sargent, D.
    Berlin, J.
    Kabbinavar, F.
    Dong, W.
    Flynn, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 25 - 25
  • [38] Phase Ib study of drozitumab combined with first-line FOLFOX plus bevacizumab (BV) in patients (pts) with metastatic colorectal cancer (mCRC).
    Lima, C. S. Rocha
    Baranda, J. C.
    Wallmark, J.
    Choi, Y.
    Royer-Joo, S.
    Portera, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [39] Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis
    Calvo, V.
    Ramirez, N.
    Saura, C.
    Vidal, M.
    Velasco, A.
    Llombart-Cussac, A.
    Cortes-Funes, H.
    Miles, D.
    Baselga, J.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Safety considerations in elderly patients with metastatic colorectal cancer (mCRC) treated with bevacizumab-containing regimens: Important information for oncology nurses from the BRiTE study
    Senko, Alice
    Samuelson, E.
    Gowland, P.
    Merriman, N.
    ONCOLOGY NURSING FORUM, 2008, 35 (03) : 506 - 506
12345